A new preventive cancer vaccine, developed through a collaboration between the University of Oxford and biotechnology company Moderna, is set to enter clinical trials this summer, marking a significant step in the use of mRNA technology beyond infectious diseases into cancer prevention.
The experimental vaccine is designed for individuals at high genetic risk of developing bowel and ovarian cancers, particularly those diagnosed with Lynch syndrome—a hereditary condition that greatly increases the likelihood of early-onset cancers due to inherited gene mutations affecting DNA repair.
Unlike conventional cancer treatments that target established tumours, the upcoming study will evaluate whether the vaccine can train the immune system to recognise and eliminate abnormal or pre-cancerous cells before they progress into malignant disease.
Researchers hope this preventive approach could open a new front in oncology, shifting focus from treatment to early immune intervention.
The trial, scheduled to begin this summer, will be among the first major studies to explore cancer prevention using Moderna’s mRNA platform, which has already been widely used in the development of Covid-19 vaccines. The technology works by delivering genetic instructions that prompt the body’s cells to produce specific proteins, thereby triggering an immune response.
In the context of cancer prevention, scientists aim to use this mechanism to present the immune system with markers associated with early cancerous changes. This, in turn, could enable the body to detect and destroy abnormal cells before they develop into full-blown tumours.
Lynch syndrome patients are considered a key target group for the study because their lifetime risk of developing certain cancers is significantly higher than that of the general population. Many develop bowel or endometrial cancers at a younger age, despite regular screening and monitoring.
Researchers involved in the project believe that intervening at the immune level could complement existing surveillance strategies and potentially reduce the need for invasive treatments later in life.
According to scientists at the University of Oxford, the trial will primarily assess the safety and immune response generated by the vaccine, while also monitoring early signals of effectiveness in preventing abnormal cell growth. If successful, larger trials will be required to confirm long-term cancer prevention outcomes.
Oxford researchers have suggested that if the approach proves successful in Lynch syndrome patients, it could potentially be adapted for other inherited cancer syndromes and even certain sporadic cancers where early molecular changes can be identified.
However, scientists caution that the field is still in its early stages, and it will take years of clinical evaluation before such vaccines could become widely available. Questions remain regarding durability of immune response, optimal timing of administration, and the identification of reliable cancer-specific targets that can be safely used for vaccination.
For patients with high genetic risk, particularly those undergoing frequent screening and preventive procedures, a successful vaccine could potentially reduce anxiety, improve quality of life, and lower long-term cancer incidence.
If successful, the Oxford–Moderna collaboration could pave the way for a new generation of preventive cancer vaccines, offering hope that some cancers may one day be stopped before they begin.
